regardless of promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. Such insurers are typically building barriers to access, like steep cost requirements and prior authorization that limit patient access. Industry b